Amyloidosis News - November 2020

Wild-Type Transthyretin: More Than What Meets the Heart

The neurologic features of patients with wild-type transthyretin are highlighted, and the variability and overlap of neurologic symptoms are categorized in this case review series. Read Article ›

Transthyretin Cardiac Amyloidosis in the African-American Population

Hereditary ATTR

Focusing on the prevalence of the Val122Ile mutation in African-American patients with hereditary transthyretin cardiac amyloidosis may lead to underestimation of this condition in this population. Read Article ›

Revealing Cardiac Amyloidosis Disguised as Hypertrophic Obstructive Cardiomyopathy

Misdiagnosis

This case study highlights the importance of selecting the appropriate imaging modality to diagnose cardiac amyloidosis. Read Article ›

Guideline-Directed Medical Therapy May Not Be Harmful in Patients with TTR-CA and Heart Failure with Reduced Ejection Fraction

Clinical Management

In a select group of patients with transthyretin cardiac amyloidosis (TTR-CA) and heart failure with reduced ejection fraction, guideline-directed medical therapy may be beneficial. Read Article ›

Patient and Family Experience of Transthyretin Amyloidosis: Results of 2 Focus Groups

Patient Journey and Experiences

Educating clinicians about transthyretin amyloidosis (ATTR) may help reduce the myriad of challenges and burdens faced by patients with ATTR and their families. Read Article ›